Literature DB >> 9806022

Maternal-fetal feline immunodeficiency virus transmission: timing and tissue tropisms.

A B Rogers1, E A Hoover.   

Abstract

The feline immunodeficiency virus (FIV) model of vertical human immunodeficiency virus type 1 transmission was used to explore the timing and tissue tropisms associated with intrauterine lentivirus infection. Cats chronically infected with FIV-B-2542 and their cesarean-derived fetuses and placentas were assayed by polymerase chain reaction and coculture at defined gestational intervals. Prevalence of fetal FIV infection was 0 at 3 weeks, 5% at 5 weeks, 38% at 7 weeks, and 60% at 9 weeks (term). Fetal tissues exhibiting the highest viral tropism were blood mononuclear cells and brain (each containing virus in 60% of FIV-positive fetuses) and thymus (47%). Maternal hematologic and virus load markers did not vary substantially with gestational stage. Therefore, fetal and/or placental maturation may determine the timing of lentivirus transmission. FIV infection prevalence in term fetuses was equivalent to that seen previously in vaginally delivered offspring, suggesting that most vertical FIV transmission occurs late in utero rather than intrapartum.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9806022     DOI: 10.1086/515692

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  21 in total

1.  Expression of regulatory T cell (Treg) activation markers in endometrial tissues from early and late pregnancy in the feline immunodeficiency virus (FIV)-infected cat.

Authors:  N N Lockett; V L Scott; C E Boudreaux; B T Clay; S B Pruett; P L Ryan; K S Coats
Journal:  Placenta       Date:  2010-08-02       Impact factor: 3.481

Review 2.  Going wild: lessons from naturally occurring T-lymphotropic lentiviruses.

Authors:  Sue VandeWoude; Cristian Apetrei
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

3.  Improved health and survival of FIV-infected cats is associated with the presence of autoantibodies to the primary receptor, CD134.

Authors:  Chris K Grant; Elizabeth A Fink; Magnus Sundstrom; Bruce E Torbett; John H Elder
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-09       Impact factor: 11.205

4.  Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro.

Authors:  Jia Ma; Suzanne Kennedy-Stoskopf; Jesse M Jaynes; Linda M Thurmond; Wayne A Tompkins
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

Review 5.  Molecular mechanisms of FIV infection.

Authors:  John H Elder; Magnus Sundstrom; Sohela de Rozieres; Aymeric de Parseval; Chris K Grant; Ying-Chuan Lin
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

Review 6.  Treatment of HIV infection in pregnant women: antiretroviral management options.

Authors:  Mona R Loutfy; Sharon L Walmsley
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  Expression of CD134 and CXCR4 mRNA in term placentas from FIV-infected and control cats.

Authors:  Veronica L Scott; Shane C Burgess; Leslie A Shack; Nikki N Lockett; Karen S Coats
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

Review 8.  Immunopathogenesis of feline immunodeficiency virus infection in the fetal and neonatal cat.

Authors:  Holly M Kolenda-Roberts; Leah A Kuhnt; Ryan N Jennings; Ayalew Mergia; Nazareth Gengozian; Calvin M Johnson
Journal:  Front Biosci       Date:  2007-05-01

9.  Feline immunodeficiency virus OrfA alters gene expression of splicing factors and proteasome-ubiquitination proteins.

Authors:  Magnus Sundstrom; Udayan Chatterji; Lana Schaffer; Sohela de Rozières; John H Elder
Journal:  Virology       Date:  2007-10-25       Impact factor: 3.616

Review 10.  Placental immunopathology in the FIV-infected cat: a role for inflammation in compromised pregnancy?

Authors:  Karen S Coats; Crystal E Boudreaux; Brittany T Clay; Nikki N Lockett; Veronica L Scott
Journal:  Vet Immunol Immunopathol       Date:  2009-10-14       Impact factor: 2.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.